U CAN-CER VIVE向 Karmanos癌症研究所捐赠 45万美元以上，用于继续研究利用射频治疗癌症-动脉网

U CAN-CER VIVE Gives $450K+ to Karmanos Cancer Institute for Continued Research in Using Radiofrequency to Treat Cancer

CISION 等信源发布 2025-04-23 21:45



可切换为仅中文







The National Cancer Institute-Designated Comprehensive Cancer Center will expand clinical trial studies for multiple cancer types

国家癌症研究所指定的综合癌症中心将扩大多种癌症类型的临床试验研究。

DETROIT

底特律

，

April 23, 2025

2025年4月23日

/PRNewswire/ -- The

/PRNewswire/ --

Barbara Ann Karmanos Cancer Institute

巴巴拉·安·卡曼诺斯癌症研究所

has been awarded

已被授予

$459,010

459,010美元

for continued research in treating cancers with radiofrequency electromagnetic fields. Leaders from

为了继续研究用射频电磁场治疗癌症。领导人来自

U CAN-CER VIVE

你能战胜癌症

Foundation, an organization that supports cancer research in

基金会，一个支持癌症研究的组织

Michigan

密歇根州

, delivered the check to Karmanos researchers in March. U CAN-CER VIVE was co-founded by

，于三月将支票交付给卡曼诺斯研究人员。U CAN-CER VIVE 由

Ryan and Kelley LaFontaine

瑞安和凯莉·拉方丹

. The funds will help open clinical trial studies in cancer treatment of breast, colorectal and pancreatic cancers, and continue studies in liver cancer with the novel, handheld, portable device, TheraBionic P1.

这笔资金将有助于开放乳腺癌、结直肠癌和胰腺癌治疗的临床试验研究，并使用新型手持便携式设备TheraBionic P1继续进行肝癌研究。

继续阅读

The U CAN-CER VIVE Foundation awarded Karmanos Cancer Institute researchers and physician-scientists a grant to expand studies using radiofrequency electromagnetic fields to treat cancer.

U CAN-CER VIVE基金会授予Karmanos癌症研究所的研究人员和医生科学家一笔资金，用于扩展使用射频电磁场治疗癌症的研究。

'U CAN-CER VIVE has supported the important research that our scientists conduct, and we are grateful to have had their continued commitment over the years that assists our labs in breakthrough research and development of novel treatments,' explained

“U CAN-CER VIVE 一直支持我们科学家开展的重要研究，多年来他们的持续承诺助力我们的实验室在突破性研究和新型治疗方案的开发上取得进展，我们对此深表感激，”

Anthony Shields

安东尼·希尔兹

, M.D., Ph.D.

医学博士，哲学博士

, medical oncologist, associate center director of Clinical Sciences and member of the

，医学肿瘤学家，临床科学副主任兼成员

Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team

胃肠道和神经内分泌肿瘤多学科团队

(MDT) at Karmanos. 'We've seen clear benefits in patients that we have prescribed the TheraBionic P1 device since we began offering this therapy in November. Since the announcement of Karmanos being the first to offer treatments with the device for advanced liver cancer, many of our clinical researchers have been looking into how this new therapy can extend treatment options for many of their patients.'.

(MDT) at Karmanos。 “自从我们十一月开始提供这种疗法以来，我们已经看到使用TheraBionic P1设备的患者有明显的益处。自从宣布Karmanos成为首家提供针对晚期肝癌的设备治疗后，我们的许多临床研究人员一直在研究这种新疗法如何能够为他们的许多患者扩展治疗选择。”

The TheraBionic P1 device was FDA-approved in

TheraBionic P1设备获得了FDA批准。

September 2023

2023年9月

to treat advanced hepatocellular carcinoma (HCC), the most common type of liver cancer. This treatment concept and device has undergone two decades of

用于治疗晚期肝细胞癌 (HCC)，这是最常见的肝癌类型。这一治疗理念和装置已经历了二十年的

research and studies

研究与学习

, which showed using the TheraBionic P1 device resulted in tumor shrinkage, blocked new cancer cell growth, and increased overall survival rates. According to TheraBionic, Inc., patients undergoing treatment in these studies did not experience debilitating side effects associated with other cancer-fighting therapies, including loss of appetite, diarrhea, and irritation of the palms and soles.

，研究显示使用TheraBionic P1设备可使肿瘤缩小、阻止新的癌细胞生长并提高总体生存率。据TheraBionic公司介绍，参与这些研究的患者在接受治疗时没有出现与其他抗癌疗法相关的严重副作用，包括食欲不振、腹泻以及手掌和脚底的刺激症状。

One patient lived nearly six years, using the device consistently months after recurrence of HCC. TheraBionic P1 is the first .

一名患者在肝细胞癌复发后，持续使用该设备数月，存活了近六年。TheraBionic P1 是首个。

FDA-approved

FDA批准

systemic therapy using radiofrequency electromagnetic fields to treat cancer.

利用射频电磁场治疗癌症的系统疗法。

The TheraBionic P1 device was co-invented by

TheraBionic P1设备是由以下人员共同发明的：

Boris Pasche

鲍里斯·帕什

, M.D., Ph.D., FACP, the president and CEO of Karmanos. In research studies, he and his co-inventor, Alexandre Barbault, learned that specific tumors react to specific tumor frequencies.

医学博士、哲学博士、美国医师协会成员，卡曼诺斯癌症研究所的总裁兼首席执行官。在研究中，他与共同发明者亚历山大·巴博取得了发现，特定肿瘤会对特定的肿瘤频率产生反应。

'The device is amplitude-modulated at tumor-specific frequencies. We discovered that different frequencies are needed for HCC, breast, pancreatic, colon cancers, and other solid tumors. Dr. Shields and our Karmanos physician-scientists are leading these studies. We look forward to the results of these clinical trials and hope to continue offering this device to patients who may need another option for treatment,' said Dr.

“该设备以肿瘤特异性频率进行幅度调制。我们发现，对于肝细胞癌、乳腺癌、胰腺癌、结肠癌和其他实体肿瘤，需要不同的频率。Shields博士和我们的Karmanos医生科学家们正在领导这些研究。我们期待这些临床试验的结果，并希望继续为那些可能需要另一种治疗选择的患者提供这种设备，”博士表示。

Pasche..

帕舍..

The device emits low levels of 27.12 MHz radiofrequency electromagnetic fields, which are amplitude-modulated at tumor-specific frequencies ranging from 200 Hz to 100,000 Hz. The patient puts a spoon-shaped antenna on their tongue to administer treatment in three one-hour sessions daily in the comfort of their own home.

该设备发出低水平的27.12 MHz射频电磁场，这些电磁场以肿瘤特异性频率（范围从200 Hz到100,000 Hz）进行幅度调制。患者将一个勺形天线放在舌头上，每天在家中舒适地进行三次一小时的治疗。

The specific low levels of radiofrequency electromagnetic fields travel throughout the patient's body to the primary tumor and its metastases, wherever they are located. The tumor-specific radiofrequency electromagnetic fields are recognized by receptors on tumor cells..

特定的低水平射频电磁场会穿过患者的身体，到达原发肿瘤及其转移灶，无论它们位于何处。肿瘤细胞上的受体会识别这些肿瘤特异性的射频电磁场。

1,2

Once recognized by the receptors, the signal transforms into growth arrest, blocking the growth of tumor cells without affecting healthy tissue. Radiofrequency levels delivered during treatment are lower than those generated by cellular phones when held close to the body.

一旦被受体识别，信号就会转化为生长停滞，阻止肿瘤细胞的生长而不影响健康组织。治疗过程中传递的射频水平低于手机靠近身体时产生的射频水平。

'U CAN-CER VIVE was born from a deeply personal place — a promise to fight for every life impacted by cancer,' said

“U CAN-CER VIVE 源自一个非常私人的地方——一个为每个受癌症影响的生命而战的承诺，”

Kelley LaFontaine

凯莉·拉方丹

, co-founder of U CAN-CER VIVE. 'This gift to Karmanos represents more than funding; it's our unwavering belief in the brilliance of

U CAN-CER VIVE的联合创始人表示：“这份给Karmanos的礼物不仅仅是一笔资金；它代表了我们对他们才华的坚定信念，

Michigan's

密歇根州的

researchers and the strength of every patient in the fight of their life. To know that this device is already changing outcomes, already giving families more time together — that's why we do what we do. We are honored to stand beside the team at Karmanos as they push the boundaries of what's possible and bring new light into the lives of so many.'.

研究人员和每位患者在生命之战中展现的力量。要知道，这个设备已经在改变结果，已经让家庭有更多时间团聚——这就是我们为什么做我们所做的事。我们很荣幸能与Karmanos团队并肩作战，因为他们正在突破可能的界限，为许多人的生活带来新的曙光。

Many of the studies that the U CAN-CER VIVE grant supports are expected to open in 2025. Currently, Karmanos has a study available for patients with

U CAN-CER VIVE 资助的许多研究预计将在2025年启动。目前，Karmanos 有一项针对患者的研究可供参与。

metastatic adenocarcinoma of the pancreas

胰腺转移性腺癌

。

For more information on clinical trials available at Karmanos and to access the clinical trials portal, visit

要了解更多关于 Karmanos 提供的临床试验信息并访问临床试验门户，请访问

karmanos.org/clinicaltrials

卡曼诺斯官网/临床试验

。

About the Barbara Ann Karmanos Cancer Institute

关于芭芭拉·安·卡曼诺斯癌症研究所

Karmanos Cancer Institute is a leader in transformative cancer care, research and education through courage, commitment and compassion. The Karmanos vision is a world free of cancer. As part of McLaren Health Care, Karmanos is the largest provider of cancer care and research in

卡曼诺斯癌症研究所通过勇气、承诺和同情心在转化癌症护理、研究和教育方面处于领先地位。卡曼诺斯的愿景是一个没有癌症的世界。作为麦克拉伦医疗保健的一部分，卡曼诺斯是密歇根州最大的癌症护理和研究提供者。

Michigan

密歇根州

. For more than 75 years, the administrative and research headquarters, along with the premier specialty cancer hospital, have been located in downtown

超过75年来，行政和研究总部以及首屈一指的专科癌症医院一直位于市中心。

Detroit

底特律

. With 17 network sites, Karmanos delivers world-renowned care and access to clinical trials throughout

通过其17个网点，Karmanos提供享誉全球的医疗服务，并为临床试验提供访问渠道。

Michigan

密歇根州

and northern

和北部的

Ohio

俄亥俄州

. The National Cancer Institute recognizes Karmanos as one of the best cancer centers in the nation with a comprehensive cancer center designation. Its academic partnership with the

国家癌症研究所认可卡曼诺斯为全国最好的癌症中心之一，并授予其综合性癌症中心的称号。它与

Wayne State University

韦恩州立大学

School of Medicine provides the framework for cancer research and education – defining new standards of care and improving survivorship. For more information, call 1-800-KARMANOS (800-527-6266) or visit

医学院为癌症研究和教育提供了框架——定义了新的护理标准并提高了生存率。欲了解更多信息，请拨打1-800-KARMANOS（800-527-6266）或访问

karmanos.org

卡曼诺斯.org

. Follow Karmanos on

关注卡曼诺斯

Facebook

，

Twitter

推特

，

领英

and

和

YouTube

。

About U CAN-CER VIVE Foundation

关于U CAN-CER VIVE基金会

Founded in 2016 by siblings

由兄妹创立于2016年

Ryan and Kelley LaFontaine

瑞安和凯莉·拉方丹

, U CAN-CER VIVE Foundation is a 501(c)(3) nonprofit organization committed to raising vital funds for cancer research. 100% of donations go directly toward funding grants for life-saving cancer research in the state of Michigan. Powered entirely by passionate volunteers, U CAN-CER VIVE is dedicated to creating a sustainable impact by supporting cutting-edge research, driving awareness, and offering hope to countless individuals and families affected by cancer.

U CAN-CER VIVE基金会是一家501(c)(3)非营利组织，致力于为癌症研究筹集重要资金。100%的捐款直接用于资助密歇根州内 lifesaving 癌症研究的拨款。完全由热情的志愿者推动，U CAN-CER VIVE 致力于通过支持尖端研究、提高意识，并为无数受癌症影响的个人和家庭带来希望，从而创造可持续的影响。

With the belief that together we CAN make a difference, U CAN-CER VIVE continues to fuel progress toward a cancer-free future..

怀着共同信念，我们一定能有所作为，U CAN-CER VIVE继续推动朝着无癌症未来迈进的进程。

To learn more or get involved, visit

要了解更多信息或参与其中，请访问

www.ucancervive.com

or follow @UCANCERVIVE on social media.

或在社交媒体上关注 @UCANCERVIVE。

1. Jimenez, H., Wang, M., Zimmerman, J.W., et al:

1. 吉梅内斯，H.，王，M.，齐默尔曼，J.W.，等：

Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2T-type voltage-gated calcium channels and Ca(2+) influx

肿瘤特异性幅度调制射频电磁场通过靶向Cav3.2型T型电压门控钙通道和Ca(2+)内流诱导肝细胞癌的分化

. EBioMedicine 44:209-224, 2019

《EBioMedicine》44卷：209-224页，2019年

2. Sharma, S., Wu, S.Y., Jimenez, H., et al:

2. 夏尔马，S.，吴，S.Y.，希门尼斯，H.，等：

Ca(2+) and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMF

Ca(2+) 和 CACNA1H 介导 AM 射频电磁场对乳腺癌脑转移的靶向抑制作用

. EBioMedicine 44:194-208, 2019

《EBioMedicine》44卷：194-208页，2019年

SOURCE Karmanos Cancer Institute

来源：卡曼诺斯癌症研究所

WANT YOUR COMPANY'S NEWS